Sam Chun Dang Pharm corrects disclosure to add new macular degeneration drug item to Canada, Middle East supply deals

Bitget2026/10/01 07:33

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

SCD corrected its prior disclosure on an Apotex deal covering exclusive Canadian supply and sales rights for its SCD411 aflibercept biosimilar.
The correction adds a new macular degeneration product for Canada plus six Middle East countries under an additional agreement dated Oct. 1, 2026.
Contract terms for the added product remain undisclosed due to the partner’s confidentiality request, with an embargo set through Oct. 1, 2036.
The filing adds a risk item: termination of the added-product agreement could trigger a termination fee within previously received milestones.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SCD - Sam Chun Dang Pharm. Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261001900395), on October 01, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Sam Chun Dang Pharm corrects disclosure to add new macular degeneration drug item to Canada, Middle East supply deals

You may also like

Crypto prices